Effective monitoring and evaluation are necessary to achieve the goals of LF elimination. After mass administration of medicines according to the guidelines established by WHO, programmes must be able to assess whether the interventions have succeeded in lowering the prevalence of infection to a level at which transmission is no longer likely to be sustainable. Transmission assessment survey (TAS) is designed to provide a simple, robust survey design for documenting that the prevalence of lymphatic filariasis among 6–7 year old children is below a predetermined threshold; to provide the evidence base for programme managers that MDA can be stopped; and to assure national governments that national programmes have achieved their elimination goals.

This manual is designed to teach personnel of national programmes to eliminate lymphatic filariasis, including regional and district health personnel, the essential elements of monitoring and evaluating national programmes to eliminate LF. The focus is on planning and implementing TAS as an input to decide whether to move from MDA to post-MDA surveillance.

Preventive Chemotherapy and Transmission Control (PCT) Department of Control of Neglected Tropical Diseases (NTD) World Health Organization 20, Avenue Appia 1211 Geneva 27, Switzerland



#### WORLD HEALTH ORGANIZATION **GLOBAL PROGRAMME TO ELIMINATE**

TRAINING IN MONITORING

AND EPIDEMIOLOGICAL ASSESSMENT OF MASS

ADMINISTRATION FOR ELIMINATING LYMPHATIC FILARIASIS

LYMPHATIC FILARIASIS

TRAINING IN MONITORING AND **EPIDEMIOLOGICAL ASSESSMENT** OF MASS DRUG ADMINISTRATION FOR ELIMINATING LYMPHATIC **FILARIASIS** 

# LARIASIS

**FACILITATORS' GUIDE** 





http://www.who,int/neglected\_diseases/en

## WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE

LYMPHATIC FILARIASIS

TRAINING IN MONITORING AND EPIDEMIOLOGICAL ASSESSMENT OF MASS DRUG ADMINISTRATION FOR ELIMINATING LYMPHATIC FILARIASIS

## LYMANIC

**FACILITATORS' GUIDE** 





WHO Library Cataloguing-in-Publication Data

Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis: facilitators' quide.

Contains slides

1. Elephantiasis, Filarial — drug therapy. 2. Filariasis — drug therapy. 3. Filariasis — epidemiology. 4. Drug therapy - methods. 5. National health programs. 6. Program evaluation 7. Teaching materials. 1. World Health Organization.

(NLM classification: WC 880)

ISBN 978 92 4 150544 4

#### © World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www. who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications—whether for sale or for non-commercial distribution— should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright\_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.


The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Italy.

WHO/HTM/NTD/PCT/2013.8


Prepartion of this document was supported by the Department for International Development of the Government of the United Kingdoms of Great Britain and Northern Ireland.



## Contents

Acknowledgements	v
Abbreviations	vii
Introduction	ix
THEORY OF TRANSMISSION ASSESSMENT SURVEYS (TAS)	
Module 1. Background	1
Module 2. Eligibility for a TAS	7
Module 3. Evaluation unit	11
Module 4. Survey design	15
Module 5. Diagnostic tests	19
Module 6. After the survey	23
Module 7. Verification of elimination	27
PRACTICAL ASPECTS OF TRANSMISSION ASSESSMENT SURVEYS	
Module 8. Survey sample builder	31
Module 9. Timetable, budget and administration	37
Module 10. Field work	41
ANNEXES	45
Annex 1. Example of information sheet on a transmission assessment	
survey training workshop	45
Annex 2. Test to be taken by participants before and after	
training (with answers)	48
Annex 3. Post-training evaluation questionnaire	51
Annex 4. Geographical, national and surveyed coverage	57
Annex 5. Advantages and disadvantages of LF diagnostic tests	59
Annex 6. Enabling macros in Excel	61








## Acknowledgements

Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis—facilitators' guide was produced under the overall supervision of Dr Lorenzo Savioli, Director, and Dr Dirk Engels, Coordinator, Department of Control of Neglected Tropical Diseases.

WHO expresses its sincere thanks to all those who contributed to preparation of this document. Special thanks are due to the following individuals: Dr Steve Ault (WHO Regional Office for the Americas), Dr Riadh Ben-Ismail (WHO Regional Office for the Eastern Mediterranean), Ms Molly Brady (RTI International), Dr Eva-Maria Christophel (WHO Regional Office for the Western Pacific), Mr Brian Chu (Task Force for Global Health, USA), Dr Aditya Prasad Dash (WHO Regional Office for South-East Asia), Dr Amadou Garba (WHO Regional Office for Africa), Prof John Gyapong (University of Ghana), Dr Kaliannagounder Krishnamoorthy (Vector Control Research Centre, India), Dr Louise Kelly Hope (Centre for Neglected Tropical Diseases, Liverpool School of tropical Medicine, United Kingdom), Dr Patrick Lammie (United States Centers for Disease Control and Prevention), Dr Adiele Onyeze (WHO Regional Office for Africa), Dr Eric Ottesen (Task Force for Global Health, USA), Dr Reda Ramzy (National Nutrition Institute, Egypt), Dr Maria Rebollo (Centre for Neglected Tropical Diseases, Liverpool School of tropical Medicine, United Kingdom), Ms Angela Weaver (United States Agency for International Development), Ms Kimberly Won (United States Center for Disease Control and Prevention), Dr Hany Ziady (WHO Regional Office for the Eastern Mediterranean) and Ms Katie Zoerhoff (RTI International).

The training modules developed by Ms Kimberly Won (United States Center for Disease Control and Prevention) formed the basis for this document. Dr Aya Yajima (WHO Department of Control of Neglected Tropical Diseases) and Dr Kazuyo Ichimori (Focal Point for Lymphatic Filariasis Elimination, WHO Department of Control of Neglected Tropical Diseases) prepared the final draft.





## Abbreviations

Ag antigenaemia

ELISA enzyme-linked immunosorbent assay

EU evaluation unit

GPELF Global Programme to Eliminate Lymphatic Filariasis

MDA mass drug administration

Mf microfilaraemia

ICT immunochromatographic test

IU implementation unit PCR polymerase chain reaction

RPRG regional programme review group
TAS transmission assessment survey
WHO World Health Organization

### 预览已结束, 完整报告链接和二维

https://www.yunbaogao.cn/report/index/report?report